Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.55
Percentage change -6.69	%

Peers: ILMN TXG GH PACB QGEN TWST FATE BEAM CRSP VRTX

| Held by: ARKG VTI IWM VB VXF IWN VBK IBB VTWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-1.08	Insider Own	4.61%	Shs Outstand	147.77M	Perf Week	-8.69%
Market Cap	1.14B	Forward P/E	-	EPS next Y	-0.70	Insider Trans	-16.46%	Shs Float	141.74M	Perf Month	-6.00%
Income	-159.49M	PEG	-	EPS next Q	-0.29	Inst Own	92.54%	Short Float	6.69%	Perf Quarter	20.03%
Sales	178.96M	P/S	6.37	EPS this Y	14.71%	Inst Trans	0.39%	Short Ratio	5.39	Perf Half Y	91.75%
Book/sh	1.37	P/B	5.59	EPS next Y	24.31%	ROA	-26.57%	Short Interest	9.49M	Perf Year	166.32%
Cash/sh	1.50	P/C	5.13	EPS next 5Y	28.67%	ROE	-62.41%	52W Range	2.28 - 9.01	Perf YTD	27.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-1.51%	ROI	-38.50%	52W High	-14.87%	Beta	1.70
Dividend TTM	-	Quick Ratio	2.81	Sales past 5Y	17.92%	Gross Margin	53.95%	52W Low	236.40%	ATR (14)	0.65
Dividend Ex-Date	-	Current Ratio	2.89	EPS Y/Y TTM	30.45%	Oper. Margin	-86.27%	RSI (14)	47.20	Volatility	6.53% 9.60%
Employees	619	Debt/Eq	1.10	Sales Y/Y TTM	5.10%	Profit Margin	-89.12%	Recom	1.25	Target Price	9.71
Option/Short	Yes / Yes	LT Debt/Eq	1.04	EPS Q/Q	52.38%	Payout	-	Rel Volume	0.89	Prev Close	8.22
Sales Surprise	3.06%	EPS Surprise	10.26%	Sales Q/Q	3.66%	Earnings	Feb 11 AMC	Avg Volume	1.76M	Price	7.67
SMA20	-1.29%	SMA50	-2.49%	SMA200	35.92%	Trades		Volume	1,563,957	Change	-6.69%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-21-25	Upgrade	Goldman	Neutral → Buy	$9
Jul-05-23	Resumed	JP Morgan	Overweight	$15
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$15
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight	$7.50 → $14
Aug-25-22	Initiated	Credit Suisse	Underperform	$8
Jun-03-22	Initiated	Piper Sandler	Neutral	$7.50
Feb-16-22	Reiterated	JP Morgan	Overweight	$75 → $50
Feb-16-22	Reiterated	Goldman	Neutral	$54 → $21
Feb-16-22	Reiterated	BTIG Research	Buy	$35 → $30
Feb-16-22	Reiterated	BofA Securities	Buy	$40 → $32
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral	$74 → $63
Oct-08-20	Resumed	BTIG Research	Buy	$60
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight	$42
Jun-03-20	Initiated	Goldman	Buy	$60
Jul-23-19	Initiated	BTIG Research	Buy	$46
Jul-22-19	Initiated	William Blair	Outperform
Jul-22-19	Initiated	Guggenheim	Buy	$47
Jul-22-19	Initiated	Goldman	Neutral	$32
Jul-22-19	Initiated	Cowen	Outperform

Show Previous Ratings

Mar-20-25 03:06PM	Adaptive Biotechnologies (ADPT): Among Stocks Insiders Are Selling In March (InsiderMonkey)
Mar-11-25 08:00AM	Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma (GlobeNewswire) +12.29%
Feb-14-25 10:44AM	Adaptive Biotechnologies price target raised to $12 from $10 at Scotiabank (TipRanks)
Feb-12-25 12:00PM	Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade (Zacks)
09:56AM	Q4 2024 Adaptive Biotechnologies Corp Earnings Call (Thomson Reuters StreetEvents)
09:40AM	Loading…
09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
02:11AM	Adaptive Biotechnologies Corp (ADPT) Q4 2024 Earnings Call Highlights: Strong MRD Revenue ... (GuruFocus.com)
Feb-11-25 06:30PM	Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:45PM	Adaptive Biotechnologies: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-10-25 07:19AM	Adaptive Biotechnologies Corp (ADPT) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-05-25 04:05PM	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire) +9.23%
Feb-04-25 10:28AM	PhaseV and Alimentiv to support execution of adaptive clinical trials for GI (Clinical Trials Arena)
Jan-23-25 05:06PM	Why Adaptive Biotechnologies Corporation (ADPT) Is Skyrocketing Now (Insider Monkey)
06:21AM	Loading…
06:21AM	Why Is Andreas Halvorsen Bullish On Adaptive Biotechnologies Corporation (ADPT) Now? (Insider Monkey)
Jan-22-25 04:05PM	Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 (GlobeNewswire) +7.52%
Jan-17-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-16-25 08:33AM	Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock? (Zacks)
Jan-15-25 10:10AM	Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year (PR Newswire) +17.96%
Jan-14-25 07:30AM	Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients (GlobeNewswire) -6.04%
Jan-07-25 07:30AM	Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025 (GlobeNewswire)
Jan-02-25 04:05PM	Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +16.32%
Dec-09-24 09:53AM	Adaptive unveils data of MRD assessment test in blood cancer treatment (Medical Device Network)
Dec-07-24 06:30PM	Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ and Its Impact on Blood Cancer Treatment Decisions (GlobeNewswire)
Dec-05-24 07:16AM	Adaptive Research and WRO to expand cancer trial access in San Francisco Bay Area (Clinical Trials Arena)
Dec-03-24 07:30AM	Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting (GlobeNewswire)
Nov-29-24 09:40AM	Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-25-24 01:55PM	Novotech report notes shift to adaptive designs in clinical trials (Clinical Trials Arena) +18.98%
Nov-15-24 09:55AM	Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know (Zacks) -8.96%
10:18AM	Loading…
Nov-08-24 10:18AM	Q3 2024 Adaptive Biotechnologies Corp Earnings Call (Thomson Reuters StreetEvents)
02:29AM	Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highlights: Strong MRD Growth Amidst ... (GuruFocus.com)
Nov-07-24 06:30PM	Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:15PM	Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
05:11PM	Adaptive Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ for Assessing Measurable Residual Disease in Mantle Cell Lymphoma (GlobeNewswire)
Nov-06-24 07:28AM	Earnings To Watch: Adaptive Biotechnologies Corp (ADPT) Reports Q3 2024 Result (GuruFocus.com)
Oct-09-24 04:05PM	Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-04-24 04:35AM	Parametric company Adaptive Insurance launches operations (Life Insurance International) +9.09%
Aug-29-24 07:30AM	Adaptive Announces IVDR Certification for clonoSEQ in European Union (GlobeNewswire)
Aug-22-24 04:03PM	Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire) +10.45%
Aug-01-24 07:00PM	Adaptive Biotechnologies (ADPT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:20PM	Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:23PM	Adaptive Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-21-24 06:00AM	3 Precision Medicine Stocks Tailoring Treatments (InvestorPlace)
Jul-15-24 12:00PM	Adaptive builds automation tools to speed up construction payments (TechCrunch)
Jul-11-24 04:05PM	Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024 (GlobeNewswire) +11.14%
May-31-24 07:30AM	Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress (GlobeNewswire)
May-29-24 04:05PM	Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-25-24 08:30AM	ARK Invest's Cathie Wood Snags These 3 Bargains Are They Right for Your Portfolio? (Benzinga)
May-24-24 09:58AM	Does Adaptive Biotechnologies Corporation (ADPT) Have Strong Growth Potential? (Insider Monkey)
May-23-24 06:00AM	Mighty Mites: 3 Small-Cap Stocks Packing a Powerful Punch (InvestorPlace)
May-16-24 02:30PM	The Agency by AGI Denim Elevates Adaptive Denim (Sourcing Journal)
May-08-24 06:43PM	Why Adaptive Biotechnologies Topped the Market Today (Motley Fool) +11.95%
12:19PM	Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:54AM	Adaptive Biotechnologies Corp (ADPT) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-07-24 07:30PM	Compared to Estimates, Adaptive Biotechnologies (ADPT) Q1 Earnings: A Look at Key Metrics (Zacks)
05:47PM	Adaptive Biotechnologies Q1 2024 Earnings: Revenue Beats Estimates Amidst Challenges (GuruFocus.com)
05:40PM	Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:37PM	Adaptive Biotechnologies: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-26-24 10:02AM	PhaseV and Quanticate partner to help sponsors run more adaptive trials (Clinical Trials Arena)
Apr-17-24 04:05PM	Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire) -11.27%
Apr-02-24 04:05PM	Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue (GlobeNewswire) -10.07%
Mar-27-24 04:30PM	The 7 Best Penny Stocks to Buy in Q2 2024 (InvestorPlace) +11.07%
08:30AM	Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024 (GlobeNewswire)
Mar-11-24 12:01AM	Team behind popular Falcon AI models unveils new startup with $20 million in funding aimed at helping companies tailor LLMs for business (Fortune)
Feb-22-24 04:05PM	Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire)
Feb-15-24 10:09AM	Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:37AM	Q4 2023 Adaptive Biotechnologies Corp Earnings Call (Thomson Reuters StreetEvents)
Feb-14-24 05:16PM	Adaptive Biotechnologies Corp (ADPT) Faces Revenue Decline Amid Growth in MRD Segment (GuruFocus.com) +8.84%
04:43PM	Adaptive Biotechnologies: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-13-24 02:23AM	Here's Why Adaptive Biotechnologies Corporation (ADPT) Declined in Q4 (Insider Monkey) -7.65%
Feb-12-24 09:16AM	Exploring Analyst Estimates for Adaptive Biotechnologies (ADPT) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Jan-29-24 04:05PM	Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024 (GlobeNewswire)
Dec-27-23 04:05PM	Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-23 05:50AM	Cathie Wood Is Loading Up on These 3 Small-Cap Stocks: Should You? (Motley Fool)
Dec-11-23 03:30PM	16 Best Penny Stocks To Buy For 2024 (Insider Monkey)
Dec-09-23 08:30AM	Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ in Patients with Blood Cancers at the 65th ASH Annual Meeting (GlobeNewswire)
Dec-05-23 07:30AM	Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting (GlobeNewswire) -7.14%
Nov-10-23 01:52PM	Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript (Insider Monkey) -18.18%
Nov-09-23 04:17PM	Adaptive Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-23 07:30AM	Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ Assay Across BeiGene's Lymphoid Malignancy Pipeline (GlobeNewswire)
Nov-02-23 04:05PM	Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023 (GlobeNewswire) +9.46%
Oct-26-23 10:02AM	Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-17-23 07:57AM	Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock? (Zacks)
Sep-27-23 05:14AM	Strength Seen in Adaptive Biotechnologies (ADPT): Can Its 9.5% Jump Turn into More Strength? (Zacks)
Sep-13-23 07:30AM	Adaptive Announces Launch of Epic Integration for clonoSEQ® (GlobeNewswire)
Aug-30-23 04:30PM	Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-28-23 11:53PM	3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List (InvestorPlace) +8.27%
Aug-24-23 10:29AM	Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks (Motley Fool) -6.62%
Aug-02-23 05:35PM	Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -12.44%
04:30PM	Adaptive Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-29-23 12:12AM	Is it Still Worthy to Invest in Adaptive Biotechnologies (ADPT)? (Insider Monkey)
Jul-19-23 08:52AM	Viking Globals Performance, AUM, and Long-Term Stock Picks (Insider Monkey)

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBINS HARLAN S	Chief Scientific Officer	Mar 24 '25	Option Exercise	6.32	1,698	10,731	1,281,222	Mar 26 06:48 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 24 '25	Sale	9.00	1,698	15,282	1,279,524	Mar 26 06:48 PM
Harlan Robins	Officer	Mar 24 '25	Proposed Sale	8.66	1,698	14,705		Mar 24 05:45 PM
PISKEL KYLE	Chief Financial Officer	Mar 14 '25	Option Exercise	6.32	2,500	15,800	271,510	Mar 17 07:34 PM
GRIFFIN MICHELLE RENEE	Director	Mar 13 '25	Sale	7.19	36,291	260,932	15,394	Mar 17 07:33 PM
GRIFFIN MICHELLE RENEE	Director	Mar 13 '25	Proposed Sale	7.19	36,291	260,861		Mar 13 05:28 PM
HERSHBERG ROBERT	Director	Mar 12 '25	Sale	7.59	53,000	402,270	69,690	Mar 12 07:48 PM
NEUPERT PETER M	Director	Mar 10 '25	Option Exercise	4.07	50,000	203,500	234,690	Mar 12 07:47 PM
NEUPERT PETER M	Director	Mar 10 '25	Sale	7.05	10,000	70,500	224,690	Mar 12 07:47 PM
HERSHBERG ROBERT	Director	Mar 12 '25	Proposed Sale	7.59	53,000	402,270		Mar 12 05:30 PM
NEUPERT PETER M	Director	Mar 10 '25	Proposed Sale	7.05	10,000	70,450		Mar 10 02:48 PM
LO FRANCIS	Chief People Officer	Mar 05 '25	Sale	6.99	20,875	145,845	332,846	Mar 06 07:22 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Mar 05 '25	Sale	6.98	26,023	181,641	347,238	Mar 06 07:22 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Mar 05 '25	Sale	6.98	44,665	311,792	392,723	Mar 06 07:21 PM
PISKEL KYLE	Chief Financial Officer	Mar 05 '25	Sale	6.98	10,320	72,072	269,010	Mar 06 07:20 PM
RUBINSTEIN JULIE	President and COO	Mar 05 '25	Sale	6.98	59,505	415,540	588,249	Mar 06 07:19 PM
ROBINS HARLAN S	Chief Scientific Officer	Mar 05 '25	Sale	6.99	96,656	675,219	1,279,524	Mar 06 07:18 PM
ROBINS CHAD M	CEO and Chairman	Mar 05 '25	Sale	6.98	117,351	819,471	2,814,350	Mar 06 07:17 PM
ROBINS CHAD M	CEO and Chairman	Mar 06 '25	Sale	7.64	102,218	780,946	2,959,249	Mar 06 07:17 PM
GRIFFIN MICHELLE RENEE	Director	Mar 06 '25	Sale	7.94	15,664	124,372	51,685	Mar 06 07:14 PM
MICHELLE GRIFFIN	Director	Mar 06 '25	Proposed Sale	7.94	15,664	124,440		Mar 06 04:10 PM
ROBINS CHAD M	CEO and Chairman	Feb 19 '25	Option Exercise	6.32	186,080	1,176,026	2,762,781	Feb 21 07:28 PM
ROBINS CHAD M	CEO and Chairman	Feb 20 '25	Option Exercise	6.32	99,107	626,356	2,675,808	Feb 21 07:28 PM
ROBINS CHAD M	CEO and Chairman	Feb 19 '25	Sale	8.46	186,080	1,574,237	2,576,701	Feb 21 07:28 PM
ROBINS CHAD M	CEO and Chairman	Feb 20 '25	Sale	8.44	99,107	836,463	2,576,701	Feb 21 07:28 PM
Chad Robins	Officer	Feb 20 '25	Proposed Sale	8.37	99,107	829,526		Feb 20 04:02 PM
Chad Robins	Officer	Feb 19 '25	Proposed Sale	8.37	186,080	1,557,490		Feb 19 04:51 PM
ROBINS CHAD M	CEO and Chairman	Feb 18 '25	Option Exercise	6.32	211,160	1,334,531	2,787,861	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 14 '25	Option Exercise	6.32	158,921	1,004,381	2,735,622	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 13 '25	Option Exercise	6.32	100,287	633,814	2,676,988	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 18 '25	Sale	8.50	211,160	1,794,860	2,576,701	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 14 '25	Sale	8.46	158,921	1,344,472	2,576,701	Feb 18 08:21 PM
ROBINS CHAD M	CEO and Chairman	Feb 13 '25	Sale	8.44	100,287	846,422	2,576,701	Feb 18 08:21 PM
Chad Robins	Officer	Feb 18 '25	Proposed Sale	8.27	211,160	1,746,293		Feb 18 05:35 PM
Chad Robins	Officer	Feb 14 '25	Proposed Sale	8.33	158,921	1,323,812		Feb 14 04:11 PM
Chad Robins	Officer	Feb 13 '25	Proposed Sale	8.52	100,287	854,445		Feb 13 05:11 PM
PISKEL KYLE	Chief Financial Officer	Nov 18 '24	Sale	4.98	248	1,235	154,330	Nov 19 06:45 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Oct 08 '24	Option Exercise	1.98	5,000	9,900	253,290	Oct 10 05:47 PM
Taylor Stacy L	SVP and General Counsel	Aug 22 '24	Sale	4.50	26,922	121,079	139,365	Aug 23 04:27 PM
STACY L TAYLOR	Officer	Aug 22 '24	Proposed Sale	4.50	26,922	121,079		Aug 22 04:18 PM

Open in Screener

HLVX

HilleVax Inc

Mar 28 • 04:00PM ET

1.59

Dollar change -0.02
Percentage change -1.24	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA PFE JNJ AZN BNTX GSK NVAX DVAX VXRT ALT

| Held by: IWM VTI VXF IWN VTWO IWC VHT IWO VTWV RSSL

Index	RUT	P/E	-	EPS (ttm)	-3.09	Insider Own	54.61%	Shs Outstand	49.47M	Perf Week	-5.36%
Market Cap	79.19M	Forward P/E	-	EPS next Y	-1.30	Insider Trans	-0.13%	Shs Float	22.61M	Perf Month	-11.67%
Income	-150.28M	PEG	-	EPS next Q	-0.31	Inst Own	35.96%	Short Float	7.03%	Perf Quarter	-14.97%
Sales	0.00M	P/S	-	EPS this Y	52.78%	Inst Trans	-4.42%	Short Ratio	8.46	Perf Half Y	-9.66%
Book/sh	3.73	P/B	0.43	EPS next Y	8.47%	ROA	-51.15%	Short Interest	1.59M	Perf Year	-89.96%
Cash/sh	3.80	P/C	0.42	EPS next 5Y	22.01%	ROE	-62.24%	52W Range	1.55 - 17.23	Perf YTD	-23.19%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-241.80%	ROI	-73.06%	52W High	-90.77%	Beta	0.78
Dividend TTM	-	Quick Ratio	14.25	Sales past 5Y	0.00%	Gross Margin	-	52W Low	2.58%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	14.25	EPS Y/Y TTM	-9.50%	Oper. Margin	-	RSI (14)	28.66	Volatility	4.66% 3.91%
Employees	90	Debt/Eq	0.14	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	2.33
Option/Short	No / Yes	LT Debt/Eq	0.12	EPS Q/Q	35.83%	Payout	-	Rel Volume	0.49	Prev Close	1.61
Sales Surprise	-	EPS Surprise	-108.14%	Sales Q/Q	-	Earnings	Mar 28 AMC	Avg Volume	188.04K	Price	1.59
SMA20	-8.28%	SMA50	-12.66%	SMA200	-44.64%	Trades		Volume	92,417	Change	-1.24%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-09-24	Downgrade	Stifel	Buy → Hold	$34 → $3
Jul-09-24	Downgrade	Leerink Partners	Outperform → Market Perform	$28 → $2
Jul-09-24	Downgrade	H.C. Wainwright	Buy → Neutral	$28 → $2
Jul-08-24	Downgrade	JP Morgan	Overweight → Neutral	$24 → $5
Jul-08-24	Downgrade	Guggenheim	Buy → Neutral
Dec-13-23	Initiated	H.C. Wainwright	Buy	$28

Mar-28-25 05:00PM	HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Nov-07-24 08:00AM	HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-14-24 12:00PM	What Makes HilleVax (HLVX) a New Buy Stock (Zacks)
Aug-08-24 07:20PM	HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Aug-01-24 11:53AM	HilleVax slashes workforce by 40% after norovirus vaccine trial failure (Pharmaceutical Technology)
04:00PM	Loading…
Jul-31-24 04:00PM	HilleVax Announces Reduction in Force (GlobeNewswire)
Jul-29-24 09:35AM	After Plunging -86.93% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax (HLVX) (Zacks)
Jul-11-24 09:35AM	Down -88.84% in 4 Weeks, Here's Why HilleVax (HLVX) Looks Ripe for a Turnaround (Zacks)
Jul-09-24 10:19AM	HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails (Zacks)
Jul-08-24 12:36PM	GRFS Stock Alert: Grifols Pops 20% on Takeover Interest (InvestorPlace) -88.34%
12:17PM	Why Is HilleVax (HLVX) Stock Down 87% Today? (InvestorPlace)
08:42AM	Takeda-spinout HilleVax sees stock sink 80% as norovirus vaccine flunks phase 2 trial in infants (FierceBiotech.com)
08:16AM	HilleVaxs norovirus vaccine ineffective in large trial of infants (BioPharma Dive)
07:30AM	HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants (GlobeNewswire)
May-23-24 02:15AM	Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX) (GuruFocus.com) -7.50%
02:26PM	Loading…
May-10-24 02:26PM	HilleVax Inc (HLVX) Reports Increased Q1 Losses, Misses Analyst Earnings Expectations (GuruFocus.com)
May-09-24 11:55PM	HLVX Stock Earnings: HilleVax Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Apr-14-24 12:52PM	10 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-06-24 01:33AM	Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX) (GuruFocus.com)
Mar-21-24 02:32AM	Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX) (GuruFocus.com)
Mar-20-24 09:53PM	HLVX Stock Earnings: HilleVax Beats EPS for Q4 2023 (InvestorPlace) -7.57%
04:00PM	HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Mar-08-24 11:55PM	Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX) (GuruFocus.com)
Feb-22-24 11:27PM	Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX) (GuruFocus.com) +5.12%
Feb-05-24 04:05PM	HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-18-24 07:00AM	HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer (GlobeNewswire)
Jan-08-24 07:00AM	HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China (GlobeNewswire)
Jan-03-24 06:28PM	HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-23 01:01PM	Insider Sell Alert: Chief Medical Officer Astrid Borkowski Sells 10,000 Shares of HilleVax Inc ... (GuruFocus.com)
09:48PM	Loading…
Dec-05-23 09:48PM	Insider Sell Alert: Chief Medical Officer Astrid Borkowski Sells 20,000 Shares of HilleVax Inc ... (GuruFocus.com)
Nov-30-23 09:55AM	Wall Street Analysts Believe HilleVax, Inc. (HLVX) Could Rally 92.19%: Here's is How to Trade (Zacks)
Nov-21-23 11:03AM	Insider Sell Alert: Chief Medical Officer Astrid Borkowski Sells 10,000 Shares of HilleVax Inc ... (GuruFocus.com)
Nov-14-23 12:00PM	HilleVax, Inc. (HLVX) Moves to Buy: Rationale Behind the Upgrade (Zacks) +11.03%
09:55AM	Does HilleVax, Inc. (HLVX) Have the Potential to Rally 107.23% as Wall Street Analysts Expect? (Zacks)
Nov-09-23 04:05PM	HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire) +6.18%
Nov-01-23 04:48PM	HilleVax to Present at Upcoming Investor Conferences (GlobeNewswire) +8.18%
Sep-26-23 04:01PM	HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-25-23 07:00AM	HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Sep-19-23 08:05PM	HilleVax Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:09PM	HilleVax Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-24-23 10:40AM	J.P. Morgan Sees up to 110% Gains in These 2 Stocks Heres Why They Could Soar (TipRanks)
Aug-14-23 05:08PM	Biotech behind 2022's largest local IPO delays norovirus vaccine (American City Business Journals) -7.26% -10.17%
07:00AM	HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Jun-07-23 09:55AM	Wall Street Analysts Predict a 56.76% Upside in HilleVax, Inc. (HLVX): Here's What You Should Know (Zacks)
May-22-23 09:55AM	How Much Upside is Left in HilleVax, Inc. (HLVX)? Wall Street Analysts Think 87.76% (Zacks)
May-12-23 04:05PM	HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-09-23 07:00AM	HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors (GlobeNewswire)
Apr-25-23 06:45AM	HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate (GlobeNewswire)

HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HERSHBERG ROBERT	See Remarks	Feb 04 '25	Sale	1.89	14,634	27,658	1,113,399	Feb 12 04:05 PM
HERSHBERG ROBERT	See Remarks	Feb 11 '25	Sale	1.76	11,901	21,003	1,101,498	Feb 12 04:05 PM
Maltbie Shane	Chief Financial Officer	Feb 11 '25	Sale	1.76	4,345	7,659	79,887	Feb 12 04:05 PM
Maltbie Shane	Chief Financial Officer	Feb 04 '25	Sale	1.89	3,946	7,458	84,232	Feb 12 04:05 PM
Kohli Aditya	Director	May 20 '24	Sale	15.45	6,000	92,689	776,878	May 22 05:40 PM
Kohli Aditya	Director	May 22 '24	Sale	14.73	6,000	88,372	764,878	May 22 05:40 PM
Kohli Aditya	Director	May 21 '24	Sale	14.21	6,000	85,230	770,878	May 22 05:40 PM
Kohli Aditya	Director	May 02 '24	Sale	14.01	6,000	84,081	783,601	May 03 07:12 PM
Kohli Aditya	Director	May 03 '24	Sale	14.15	723	10,233	782,878	May 03 07:12 PM
Kohli Aditya	Director	May 01 '24	Sale	14.03	175	2,456	789,601	May 03 07:12 PM
Frazier Life Sciences X, L.P.	10% Owner	Apr 04 '24	Buy	14.50	8,850	128,325	8,544,187	Apr 08 04:22 PM
Kohli Aditya	Director	Apr 03 '24	Sale	14.93	6,000	89,582	801,776	Apr 05 05:48 PM
Kohli Aditya	Director	Apr 04 '24	Sale	14.71	6,000	88,245	795,776	Apr 05 05:48 PM
Kohli Aditya	Director	Apr 05 '24	Sale	14.44	6,000	86,640	789,776	Apr 05 05:48 PM

ADPT

Adaptive Biotechnologies Corp

HLVX

HilleVax Inc

Upgrade your FINVIZ experience